These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Risk of venous thromboembolism with drospirenone-containing oral contraceptives. Brown DA, Vartan CM. Am J Health Syst Pharm; 2011 Jun 01; 68(11):1003-10. PubMed ID: 21593228 [Abstract] [Full Text] [Related]
29. The association between drospirenone and hyperkalemia: a comparative-safety study. Bird ST, Pepe SR, Etminan M, Liu X, Brophy JM, Delaney JA. BMC Clin Pharmacol; 2011 Dec 30; 11():23. PubMed ID: 22208934 [Abstract] [Full Text] [Related]
31. Drospirenone: high risk of venous thrombosis. Prescrire Int; 2011 Feb 30; 20(113):43-5. PubMed ID: 21488592 [Abstract] [Full Text] [Related]
32. Association of Oral Contraceptives With Drug-Induced QT Interval Prolongation in Healthy Nonmenopausal Women. Salem JE, Dureau P, Bachelot A, Germain M, Voiriot P, Lebourgeois B, Trégouët DA, Hulot JS, Funck-Brentano C. JAMA Cardiol; 2018 Sep 01; 3(9):877-882. PubMed ID: 30073300 [Abstract] [Full Text] [Related]
33. Venous Thromboembolic Risk of Estradiol Valerate-Dienogest Compared with Ethinyl Estradiol-Levonorgestrel Combined Oral Contraceptives. Bauerfeind A, von Stockum S, Boehnke T, Heinemann K. Obstet Gynecol; 2024 Mar 01; 143(3):431-434. PubMed ID: 38227942 [Abstract] [Full Text] [Related]
34. Epidemiology of hormonal contraceptives-related venous thromboembolism. Hugon-Rodin J, Gompel A, Plu-Bureau G. Eur J Endocrinol; 2014 Dec 01; 171(6):R221-30. PubMed ID: 25012200 [Abstract] [Full Text] [Related]
35. Venous and pulmonary thromboembolism and combined hormonal contraceptives. Systematic review and meta-analysis. Martínez F, Ramírez I, Pérez-Campos E, Latorre K, Lete I. Eur J Contracept Reprod Health Care; 2012 Feb 01; 17(1):7-29. PubMed ID: 22239262 [Abstract] [Full Text] [Related]
36. Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism. Hugon-Rodin J, Horellou MH, Conard J, Gompel A, Plu-Bureau G. Thromb Haemost; 2018 May 01; 118(5):922-928. PubMed ID: 29614525 [Abstract] [Full Text] [Related]
37. Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users. Samuelsson E, Hägg S. Acta Obstet Gynecol Scand; 2004 Jul 01; 83(7):674-81. PubMed ID: 15225194 [Abstract] [Full Text] [Related]
38. Systematic review and meta-analysis of the association of combined oral contraceptives on the risk of venous thromboembolism: The role of the progestogen type and estrogen dose. Oedingen C, Scholz S, Razum O. Thromb Res; 2018 May 01; 165():68-78. PubMed ID: 29573722 [Abstract] [Full Text] [Related]
39. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. van Vlijmen EF, Brouwer JL, Veeger NJ, Eskes TK, de Graeff PA, van der Meer J. Arch Intern Med; 2007 Feb 12; 167(3):282-9. PubMed ID: 17296885 [Abstract] [Full Text] [Related]
40. Drospirenone Litigation: Does the Punishment Fit the Crime? Batur P, Casey PM. J Womens Health (Larchmt); 2017 Feb 12; 26(2):99-102. PubMed ID: 27854556 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]